Cutaneous Eruption due to Telaprevir
| dc.Type | Article | pt_BR |
| dc.contributor.author | Falcão, Eduardo Mastrangelo Marinho | |
| dc.contributor.author | Trope, Beatriz Moritz | |
| dc.contributor.author | Godinho, Mariana Marteleto | |
| dc.contributor.author | Carneiro, Leonardo Hoehl | |
| dc.contributor.author | Araújo Neto, João Marcello de | |
| dc.contributor.author | Nogueira, Cristiane Alves Villela | |
| dc.contributor.author | Silva, Marcia Ramos e | |
| dc.date.accessioned | 2022-07-29T16:48:29Z | |
| dc.date.available | 2022-07-29T16:48:29Z | |
| dc.date.issued | 2015 | |
| dc.description | p. 253–262.: il. color. | |
| dc.description.abstract | Hepatitis C virus (HCV) chronically infects 0.5–3% of the world population. A large group of patients develop cirrhosis and its complications. Since 2011, telaprevir and boceprevir are used, improving the disease evolution. One of the main side effects of these drugs is skin eruption. We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. In the ninth week, he presented a severe rash that re quired the interruption of this drug. We emphasize the importance of early recognition and appropriate management of adverse skin reaction. | |
| dc.identifier.citation | FALCÃO, Eduardo Mastrangelo Marinho et al. Cutaneous Eruption due to Telaprevir. Case Rep Dermatology, v. 7, p. 253–262, 2015. | |
| dc.identifier.issn | 1662-6567 | |
| dc.identifier.uri | http://sr-vmlxaph03:8080/jspui/handle/123456789/9666 | |
| dc.publisher | Case Rep Dermatology | pt_BR |
| dc.subject | Hepatite C | pt_BR |
| dc.subject | Hepatitis C | pt_BR |
| dc.subject | Inibidores do Citocromo P-450 CYP3A | pt_BR |
| dc.subject | Cytochrome P-450 CYP3A Inhibitors | pt_BR |
| dc.subject | Erupção por Droga | pt_BR |
| dc.subject | Drug Eruptions | pt_BR |
| dc.title | Cutaneous Eruption due to Telaprevir | pt_BR |